102 related articles for article (PubMed ID: 23933938)
1. Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis.
Sumida Y; Naito Y; Tanaka S; Sakai K; Inada Y; Taketani H; Kanemasa K; Yasui K; Itoh Y; Okanoue T; Yoshikawa T
Hepatogastroenterology; 2013 Sep; 60(126):1445-50. PubMed ID: 23933938
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
[TBL] [Abstract][Full Text] [Related]
4. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
[TBL] [Abstract][Full Text] [Related]
5. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
[TBL] [Abstract][Full Text] [Related]
6. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.
Yakaryilmaz F; Guliter S; Savas B; Erdem O; Ersoy R; Erden E; Akyol G; Bozkaya H; Ozenirler S
Intern Med J; 2007 Apr; 37(4):229-35. PubMed ID: 17388862
[TBL] [Abstract][Full Text] [Related]
7. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
8. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
9. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
Hoofnagle JH; Van Natta ML; Kleiner DE; Clark JM; Kowdley KV; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J;
Aliment Pharmacol Ther; 2013 Jul; 38(2):134-43. PubMed ID: 23718573
[TBL] [Abstract][Full Text] [Related]
10. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results.
Pietu F; Guillaud O; Walter T; Vallin M; Hervieu V; Scoazec JY; Dumortier J
Clin Res Hepatol Gastroenterol; 2012 Apr; 36(2):146-55. PubMed ID: 22154224
[TBL] [Abstract][Full Text] [Related]
14. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
[TBL] [Abstract][Full Text] [Related]
17. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease.
Nobili V; Manco M; Devito R; Ciampalini P; Piemonte F; Marcellini M
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1553-61. PubMed ID: 17206944
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity].
Chavarría-Arciniega S; López-Alvarenga JC; Uribe-Uribe NO; Herrera-Hernández M; González-Barranco J
Rev Invest Clin; 2005; 57(4):505-12. PubMed ID: 16315634
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease in severely obese subjects.
Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
[TBL] [Abstract][Full Text] [Related]
20. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
